{"commentary":{"count":157,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":80,"podcast":51,"x_thread":25,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04269200\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DUO-E","nct_id":"NCT04269200","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=duo-e-nct04269200. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"DUO-E","arms":[{"description":"Platinum-based chemotherapy and durvalumab placebo followed by maintenance durvalumab placebo and olaparib placebo (tablets).","label":"Arm A (control)","type":"ACTIVE_COMPARATOR"},{"description":"Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib placebo","label":"Arm B (durvalumab+placebo)","type":"EXPERIMENTAL"},{"description":"Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib.","label":"Arm C (durvalumab+olaparib)","type":"EXPERIMENTAL"}],"collaborators":["GOG Foundation","European Network of Gynaecological Oncological Trial Groups (ENGOT)"],"completion_date":{"date":"2027-04-01","type":"ESTIMATED"},"conditions":["Endometrial Neoplasms"],"enrollment":{"count":805,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"olaparib","type":"DRUG"},{"name":"durvalumab","type":"BIOLOGICAL"},{"name":"durvalumab placebo","type":"DRUG"},{"name":"olaparib placebo","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"}],"last_update":"2026-08-07","lead_sponsor":"AstraZeneca","official_title":"A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-07-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) According to RECIST 1.1, Based on Investigator Assessments","timeFrame":"At baseline, every 9 weeks (wks) up to 18 wks, then every 12 wks until objective radiological disease progression. Assessed until 12 Apr 2023 DCO (08 Jul 2024 DCO for China cohort), up to 50 months"}],"references":[{"citation":"Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Liu X, Nieuwenhuysen EV; DUO-E Investigators. Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer. Future Oncol. 2026 Apr;22(9):1031-1046. doi: 10.1080/14796694.2026.2638677. Epub 2026 Apr 6.","pmid":"41943281","type":"DERIVED"},{"citation":"Nishio S, Nishikawa T, Mori M, Kamiura S, Sumi T, Yunokawa M, Imai Y, Kondo E, Takehara K, Takano H, Kudaka W, Kado N, Yamagami W, Kato H, Nishino K, Usami T, Hamanishi J, Nii M, Takaya I, Okamoto A. Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial. J Gynecol Oncol. 2025 Jul;36(4):e118. doi: 10.3802/jgo.2025.36.e118.","pmid":"40590327","type":"DERIVED"},{"citation":"Bogani G, Monk BJ, Powell MA, Westin SN, Slomovitz B, Moore KN, Eskander RN, Raspagliesi F, Barretina-Ginesta MP, Colombo N, Mirza MR. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Ann Oncol. 2024 May;35(5):414-428. doi: 10.1016/j.annonc.2024.02.006. Epub 2024 Feb 29.","pmid":"38431043","type":"DERIVED"},{"citation":"Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21.","pmid":"37864337","type":"DERIVED"}],"start_date":{"date":"2020-05-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer","url":"https://clinicaltrials.gov/study/NCT04269200"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/duo-e-nct04269200"}